Skip to main content

Table 1 Subject characteristics of all the patients recruited for the smoking cessation.

From: Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research study

 

Non-smoking controls

Asymptomatic Smokers

Smokers with smokers

Chronic asthma bronchitis/COPD

Subjects (n)

30

25

15

21

Female/male

7/23

15/10

9/6

14/7

Age yrs

56 ± 8

42 ± 12

42 ± 12

56 ± 10

Pack-yrs

4 ± 8

23 ± 15

22 ± 14

39 ± 15

Post-bronchodilator

   

FVC L**

4.9 ± 0.71

3.9 ± 0.60

4.2 ± 0.70

3.0 ± 0.66

FVC % pred

102 ± 9

99 ± 14

103 ± 17

102 ± 38

FEV1 L**

4.0 ± 0.65

3.2 ± 0.49

3.5 ± 0.55

2.1 ± 0.72

FEV1% pred*

104 ± 12

97 ± 8

99 ± 14

79 ± 8

FEV1/FVC

82 ± 4.4

83 ± 1

80 ± 9

69 ± 15

  1. Data presented as mean ± SD or median (range). FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in one second; *: p < 0.01; **: p < 0.001. #: baseline levels at once after smoking cessation.